Bifogade filer
Kurs & Likviditet
Kalender
2025-02-21 | Bokslutskommuniké 2024 |
2024-11-15 | Kvartalsrapport 2024-Q3 |
2024-10-21 | Extra Bolagsstämma 2024 |
2024-08-23 | Kvartalsrapport 2024-Q2 |
2024-06-28 | Årsstämma |
2024-05-29 | Kvartalsrapport 2024-Q1 |
2024-05-17 | X-dag ordinarie utdelning CLS B 0.00 SEK |
2024-04-25 | Split CLS B 200:1 |
2024-02-23 | Bokslutskommuniké 2023 |
2023-11-17 | Kvartalsrapport 2023-Q3 |
2023-08-25 | Kvartalsrapport 2023-Q2 |
2023-06-29 | Årsstämma |
2023-06-22 | X-dag ordinarie utdelning CLS B 0.00 SEK |
2023-06-08 | Extra Bolagsstämma 2023 |
2023-05-25 | Kvartalsrapport 2023-Q1 |
2023-02-23 | Bokslutskommuniké 2022 |
2022-11-22 | Extra Bolagsstämma 2022 |
2022-11-17 | Kvartalsrapport 2022-Q3 |
2022-08-25 | Kvartalsrapport 2022-Q2 |
2022-06-29 | X-dag ordinarie utdelning CLS B 0.00 SEK |
2022-06-28 | Årsstämma |
2022-05-19 | Kvartalsrapport 2022-Q1 |
2022-02-24 | Bokslutskommuniké 2021 |
2021-11-18 | Kvartalsrapport 2021-Q3 |
2021-08-24 | Kvartalsrapport 2021-Q2 |
2021-06-29 | X-dag ordinarie utdelning CLS B 0.00 SEK |
2021-06-28 | Årsstämma |
2021-05-19 | Kvartalsrapport 2021-Q1 |
2021-03-31 | Extra Bolagsstämma 2021 |
2021-02-26 | Bokslutskommuniké 2020 |
2020-11-19 | Kvartalsrapport 2020-Q3 |
2020-08-26 | Kvartalsrapport 2020-Q2 |
2020-06-12 | X-dag ordinarie utdelning CLS B 0.00 SEK |
2020-06-11 | Årsstämma |
2020-05-28 | Kvartalsrapport 2020-Q1 |
2020-02-28 | Bokslutskommuniké 2019 |
2019-11-21 | Kvartalsrapport 2019-Q3 |
2019-08-22 | Kvartalsrapport 2019-Q2 |
2019-06-12 | X-dag ordinarie utdelning CLS B 0.00 SEK |
2019-05-17 | Årsstämma |
2019-05-16 | Kvartalsrapport 2019-Q1 |
2019-03-18 | Extra Bolagsstämma 2019 |
2019-02-14 | Bokslutskommuniké 2018 |
2018-11-22 | Kvartalsrapport 2018-Q3 |
2018-08-23 | Kvartalsrapport 2018-Q2 |
2018-06-20 | Årsstämma |
2018-06-14 | X-dag ordinarie utdelning CLS B 0.00 SEK |
2018-05-24 | Kvartalsrapport 2018-Q1 |
2018-05-18 | Extra Bolagsstämma 2018 |
2018-02-22 | Bokslutskommuniké 2017 |
2017-11-16 | Kvartalsrapport 2017-Q3 |
2017-07-17 | Kvartalsrapport 2017-Q2 |
2017-06-28 | X-dag ordinarie utdelning CLS B 0.00 SEK |
2017-06-27 | Årsstämma |
2017-05-18 | Kvartalsrapport 2017-Q1 |
2017-01-31 | Bokslutskommuniké 2016 |
2017-01-20 | Extra Bolagsstämma 2017 |
2016-11-17 | Kvartalsrapport 2016-Q3 |
2016-08-18 | Kvartalsrapport 2016-Q2 |
2016-06-16 | Årsstämma |
2016-05-19 | Kvartalsrapport 2016-Q1 |
2016-02-21 | Bokslutskommuniké 2015 |
2015-11-19 | Kvartalsrapport 2015-Q3 |
2015-08-20 | Kvartalsrapport 2015-Q2 |
2015-06-12 | X-dag ordinarie utdelning CLS B 0.00 SEK |
2015-06-11 | Årsstämma |
2015-05-21 | Kvartalsrapport 2015-Q1 |
2015-02-23 | Bokslutskommuniké 2014 |
2014-11-14 | Kvartalsrapport 2014-Q3 |
2014-08-20 | Kvartalsrapport 2014-Q2 |
2014-06-18 | X-dag ordinarie utdelning CLS B 0.00 SEK |
2014-06-17 | Årsstämma |
2014-05-22 | Kvartalsrapport 2014-Q1 |
2014-02-24 | Bokslutskommuniké 2013 |
2013-11-22 | Kvartalsrapport 2013-Q3 |
2013-09-19 | Extra Bolagsstämma 2013 |
2013-08-20 | Kvartalsrapport 2013-Q2 |
2013-06-10 | X-dag ordinarie utdelning CLS B 0.00 SEK |
2013-06-07 | Årsstämma |
2013-05-24 | Kvartalsrapport 2013-Q1 |
2013-02-25 | Bokslutskommuniké 2012 |
2012-11-23 | Kvartalsrapport 2012-Q3 |
2012-08-24 | Kvartalsrapport 2012-Q2 |
2012-06-08 | X-dag ordinarie utdelning CLS B 0.00 SEK |
2012-06-07 | Årsstämma |
2012-04-20 | Kvartalsrapport 2012-Q1 |
2012-01-09 | Bokslutskommuniké 2011 |
2012-01-04 | Extra Bolagsstämma 2012 |
2011-11-21 | Kvartalsrapport 2011-Q3 |
2011-09-26 | Kapitalmarknadsdag 2010 |
2011-08-22 | Kvartalsrapport 2011-Q2 |
2011-06-10 | Årsstämma |
2011-05-20 | Kvartalsrapport 2011-Q1 |
2011-02-24 | Bokslutskommuniké 2010 |
2010-11-24 | Kvartalsrapport 2010-Q3 |
2010-08-25 | Kvartalsrapport 2010-Q2 |
2010-05-28 | X-dag ordinarie utdelning CLS B 0.00 SEK |
2010-05-26 | Kvartalsrapport 2010-Q1 |
2010-02-26 | Bokslutskommuniké 2009 |
2009-11-30 | Kvartalsrapport 2009-Q3 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
Lund, Sweden - November 9, 2023 - Clinical Laserthermia Systems AB (publ) ("CLS" or "the Company") today announces that their US subsidiary CLS Americas has signed a Mobile Service Provider (MSP) Agreement with KASRAEIAN Urology of Jacksonville, FL in The U.S.
Under the agreement, CLS provides its FDA 510(k) cleared TRANBERG Thermal Therapy System in a bundled service offering, including sterile disposables, training, and on-site clinical and technical support to KASRAEIAN Urology physicians and staff during procedures. KASRAEIAN Urology utilizes the latest technologies, devices, and treatments in order to provide the best options and outcomes for their prostate cancer patients.
"CLS Americas is very pleased with the increasing market adoption of our Mobile Services Program by leading professional clinics like KASRAEIAN Urology. It allows them to gain access to our image-guided TRANBERG focal laser ablation system without any capital equipment expense," said Michael Magnani, president of CLS Americas. "We are thrilled to see leading physicians, clinics, and organizations adopting our TRANBERG Laser to provide prostate cancer treatments."
"CLS Americas mobile services offering to urology clinics with prostate cancer programs is being well received and with adoption showing good progress. I can proudly say that the hard work by CLS Americas, to deliver best in class services, is generating results.", says Dan J Mogren, CEO of CLS AB.
For more information, please contact:
Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Phone: +46 (0) 70-590 11 40
E-mail: dan.mogren@clinicallaser.com
About Kasraeian Urology
For more information, visit: Jacksonville, FL Urology | Kasraeian Urology (https://kasraeianurology.com/)
About CLS
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB.
For more information about CLS, please visit the Company's website: clinicallaser.se (http://file/C:/Users/anna.spangs/Workplace/Paues%20%C3%85berg/Kunder/Clinial%20Laserthermia%20Systems/clinicallaser.se).